Eli Lilly and [LLY] vs Medicus Pharma [MDPLD] Detailed Stock Comparison

Eli Lilly and Company

NYSE
Loading...

Medicus Pharma Ltd.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Eli Lilly and Company wins in 9 metrics, Medicus Pharma Ltd. wins in 2 metrics, with 1 ties. Eli Lilly and Company appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Eli Lilly and Company Medicus Pharma Ltd. Better
P/E Ratio (TTM) 40.09 -1.47 Eli Lilly and Company
Price-to-Book Ratio 31.01 3.90 Medicus Pharma Ltd.
Debt-to-Equity Ratio 165.31 0.10 Medicus Pharma Ltd.
PEG Ratio 0.79 N/A N/A
EV/EBITDA 26.61 0.00 Tie
Profit Margin (TTM) 31.67% 0.00% Eli Lilly and Company
Operating Margin (TTM) 44.90% 0.00% Eli Lilly and Company
EBITDA Margin (TTM) 44.90% N/A N/A
Return on Equity 101.16% -841.91% Eli Lilly and Company
Return on Assets (TTM) 19.42% -358.37% Eli Lilly and Company
Free Cash Flow (TTM) $5.96B $-4.16M Eli Lilly and Company
Dividend Yield 0.60% N/A N/A
1-Year Return 38.28% N/A N/A
Price-to-Sales Ratio (TTM) 12.63 N/A N/A
Enterprise Value $843.37B $0 Eli Lilly and Company
EV/Revenue Ratio 12.94 N/A N/A
Gross Profit Margin (TTM) 82.52% N/A N/A
Revenue per Share (TTM) $73 $0 Eli Lilly and Company
Earnings per Share (Diluted) $22.94 $-2.54 Eli Lilly and Company
Beta (Stock Volatility) 0.50 N/A N/A
Short % of Float 0.97% N/A N/A

Eli Lilly and Company vs Medicus Pharma Ltd. Stock Performance Analysis

Loading Price Chart...

LLY
MDPLD

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Eli Lilly and Company-0.32%-1.72%12.38%14.18%6.32%4.53%
Medicus Pharma Ltd.1.78%0.00%0.00%0.00%0.00%0.00%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Eli Lilly and Company38.28%153.07%418.42%1,433.98%2,935.09%1,988.48%
Medicus Pharma Ltd.N/AN/AN/AN/AN/AN/A

Performance & Financial Health Analysis: Eli Lilly and Company vs Medicus Pharma Ltd.

MetricLLYMDPLD
Market Information
Market Cap i$821.31BN/A
Market Cap CategoryMega capN/A
10 Day Avg. Volume i2,387,47620,091
90 Day Avg. Volume i2,777,74936,712
Last Close$1,129.35$2.86
52 Week Range$623.78 - $1,182.73$1.80 - $6.00
% from 52W High-4.51%-52.33%
All-Time High$1,182.73 (Jun 08, 2026)$3.00 (Jan 24, 2025)
% from All-Time High-4.51%-4.67%
Growth Metrics
Quarterly Revenue Growth0.43%N/A
Quarterly Earnings Growth0.51%N/A
Financial Health
Profit Margin (TTM) i0.32%0.00%
Operating Margin (TTM) i0.45%0.00%
Return on Equity (TTM) i1.01%-8.42%
Debt to Equity (MRQ) i165.310.10
Cash & Liquidity
Book Value per Share (MRQ)$29.66$0.73
Cash per Share (MRQ)$8.14N/A
Operating Cash Flow (TTM) i$16.81B$-4,987,008
Levered Free Cash Flow (TTM) i$1.95B$-6,784,140
Dividends
Last 12-Month Dividend Yield i0.60%N/A
Last 12-Month Dividend i$6.23N/A

Valuation & Enterprise Metrics Analysis: Eli Lilly and Company vs Medicus Pharma Ltd.

MetricLLY (Apr 24, 2026)MDPLD (Mar 31, 2025)
Price Ratios
P/E Ratio (TTM) i40.09-1.47
Forward P/E i21.82N/A
PEG Ratio i0.79N/A
Price to Sales (TTM) i12.63N/A
Price to Book (MRQ) i31.013.90
Market Capitalization
Market Capitalization i$821.31B$22.45M
Enterprise Value i$843.37B$0
Enterprise Value Metrics
Enterprise to Revenue i12.94N/A
Enterprise to EBITDA i26.610.00
Risk & Other Metrics
Beta i0.50N/A
Book Value per Share (MRQ) i$29.66$0.73

Financial Statements Comparison: Eli Lilly and Company vs Medicus Pharma Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricLLY (2025)MDPLD (2023)
Revenue/Sales i65.18B0
Cost of Goods Sold i11.05BN/A
COGS % of Revenue i17.0%-
Gross Profit i54.13BN/A
Gross Margin i83.0%-
Research & Development i13.34B193,578
Operating Income (EBIT) i29.70B-3.01M
Operating Margin i45.6%-
EBITDA i35.09B-6.72M
EBITDA Margin i53.8%-
Pre-Tax Income i25.73B-6.78M
Pre-Tax Income % of Revenue i39.5%-
Income Tax i5.09BN/A
Income Tax % of Revenue i7.8%-
Net Income (Profit) i20.64B-6.78M
Profit Margin i31.7%-

Balance Sheet & Liquidity Metrics

MetricLLY (2025)MDPLD (2023)
Cash & Equivalents i7.27B1.72M
Total Current Assets i55.63B1.89M
Total Current Assets % of Revenue i85.3%-
Total Current Liabilities i35.23B1.09M
Total Current Liabilities % of Revenue i54.0%-
Long-Term Debt i40.87BN/A
Long-Term Debt % of Revenue i62.7%-
Total Shareholders Equity i26.54B805,800
Retained Earnings i24.47B-19.18M
Retained Earnings % of Revenue i37.5%-
Property, Plant & Equipment i13.49BN/A

Cash Flow Statement Comparison

MetricLLY (2025)MDPLD (2023)
Operating Cash Flow i23.60B-4.99M
Operating Cash Flow % of Revenue i36.2%-
Capital Expenditures i-7.84BN/A
Free Cash Flow i5.96B-4.16M
FCF Margin i9.2%-
Debt Repayment i-778.00MN/A
Common Stock Repurchase i-4.11BN/A

Short Interest & Institutional Ownership Analysis

MetricLLYMDPLD
Shares Short i7.70MN/A
Short Ratio i2.73N/A
Short % of Float i0.97%N/A
Shares Outstanding i894.80M8.08M
Float Shares i890.99MN/A
% Held by Insiders i0.17%55.81%
% Held by Institutions i84.77%0.00%
% Held by Public i15.06%44.19%

Dividend Analysis & Yield Comparison: Eli Lilly and Company vs Medicus Pharma Ltd.

MetricLLYMDPLD
Last 12-Month Dividend i$6.23N/A
Last 12-Month Dividend Yield i0.60%N/A
3-Year Avg Annual Dividend i$5.44N/A
3-Year Avg Dividend Yield i0.18%N/A
3-Year Total Dividends i$16.32N/A
Ex-Dividend DateFeb 13, 2026N/A